Viewing Study NCT01605032


Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-02-23 @ 3:01 PM
Study NCT ID: NCT01605032
Status: COMPLETED
Last Update Posted: 2020-08-20
First Post: 2012-03-07
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Sponsor: Albert Einstein College of Medicine
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None DS Stage I Plasma Cell Myeloma View
None DS Stage II Plasma Cell Myeloma View
None DS Stage III Plasma Cell Myeloma View
None Refractory Plasma Cell Myeloma View
Keywords: